



#### FICCI HEAL 2020

## "Post-COVID Healthcare World" - The New Beginning

29th Sep - 1st Oct, 2020

## **Conference Program**

As on September 18, 2020

FICCI has been organizing its annual healthcare conference, FICCI HEAL since 2007 supported by Ministry of Health & Family Welfare and recently NITI Aayog, Government of India. Over the years, this has evolved as a landmark event and a credible platform for health industry stakeholders for sharing knowledge and best practices. The 14<sup>th</sup> edition of FICCI HEAL on the theme, "Post-COVID Healthcare World" - The New Beginning" is scheduled from 29th September to 1st October, 2020.

COVID-19 has impacted the entire world and brought in unprecedented challenges in every aspect- health, economic and social. Healthcare, being at the epicenter, is amongst the worst affected sector. In India, while the government has taken numerous measures to successfully slow down the spread of virus in the initial months, the pandemic has uncovered the stark inadequacies of our healthcare system.

As healthcare providers continue to put colossal efforts in fighting against the pandemic by finding ways to manage the vulnerable and affected, the reverberations of the current crises are being felt across spectrum, heralding the onset of irreversible changes to come. The ability to deal with these new and accentuated challenges and our resilience will determine our success to adjust to the new normal and be prepared for the post-COVID world.

Along with the challenges, it is expected that the current scenario will open up a plethora of opportunities giving way to a transformed healthcare delivery system- including newer care delivery models, enhanced use of digital tools and other technologies, greater focus on preventive and primary care along with point of care and home based care, restructured facilities and operating models, and boost to local manufacturing as well as R&D in products and treatment for better health outcomes.

This calls for strengthening of Public Private Partnerships as well as other stakeholder collaborations, rethinking of processes and policies and adopting a more patient-centric as well as community-centric approach.

FICCI HEAL 2020 is an endeavor to bring together all the relevant stakeholders to share their experiences and deliberate on the solutions and reforms for the post-COVID healthcare. The conference would be a conglomeration of CEO's, policy makers, national and international leaders from healthcare and allied industries.

The three-day conference will be organised on a virtual platform and will include Keynote Addresses, Panel discussions as well as Plenary Sessions covering the entire spectrum of healthcare- public health, care delivery, pharmaceuticals, diagnostics, medical devices, integration of traditional medicine as well as digital health.



## Day-1

10:00 am – 11:15 am	Opening Session
(Hall-1)	Welcome Address
(Hall-1)	<b>Dr Alok Roy</b> , Chair, FICCI Health Services Committee and Chairman, Medica Group of Hospitals
	Keynote Address
	Prof Ashish Jha, Dean, Brown University School of Public Health and Professor of Health Services, Policy and Practice*
	Concluding Remarks and Vote of Thanks
	Dr Harsh Mahajan, Co-Chair, FICCI Health Services Committee & Founder & Chief Radiologist, Mahajan Imaging Centre
	Session Moderator
	Ms Shobha Mishra Ghosh, Assistant Secretary General, FICCI
11:15 am – 11:30 am	Break
11:30 pm- 12:15 pm	FICCI Healthcare Excellence Awards
(Hall-3)	Treet freathcare Excellence Awards
	Chief Guest: Mr Rajiv Gauba, Cabinet Secretary, GoI*
	Guest of Honour: Mr C K Mishra, Former Secretary, MoEFCC and MoHFW, Gol
	<b>Moderator and Compere: Dr Narottam Puri</b> , Advisor, FICCI Health Services Committee; Former Chairman- NABH; Advisor-Medical Operations & Chairman- Fortis Medical Council, Fortis Healthcare Ltd.
12:15 pm – 12:30pm	Break
12:30 pm – 1:00 pm	Keynote Address-
(Hall-1)	Impact of COVID on Society and Culture
	Mr T V Mohandas Pai, Adviser, FICCI Skills Committee & Chairman, Manipal Global Education
	Introduction by Mr Gautam Khanna, Co-Chair, FICCI Healthservices Committee and CEO, P D Hinduja Hospital



Business Sessions	Scientific Sessions
1:00 pm – 2:15 pm (Hall-1)	1:00 pm – 2:30 pm (Hall-2)
Changing landscape of Pharma Industry	Private Healthcare at the forefront of battle with COVID-19: From Strategy to Frontline Trenches
within the international pharmaceutical market. Although India has been the leading exporter of generic drugs across the world, it was dependant on China for more than two-thirds of its bulk drug needs. India is already working towards creating this crisis into a huge opportunity through internalizing the entire supply chain for becoming an end-to-end giant in the pharma supply chain. A strong pharma industry has always been a pillar of affordable healthcare and one can expect this trend to further strengthen now. As the pharma companies hurry to develop drugs and vaccine to combat the pandemic, they are also reshaping the pharmaceutical landscape for the future-whether it is business strategies, production and supply chains or R&D.  This session will have experts to deliberate on-  Impact of the COVID crisis and key imperatives for Pharma sector as it emerges out of the pandemic  Future of work in the healthcare ecosystem – impact on value pools, new areas of innovation	The sudden outbreak is a reminder that throughout history, mankind has survived many similar epidemic diseases that have caused huge numbers of death and suffering. Many of the worst worldwide outbreaks have killed millions. Health-care workers (HCWs) who are at the frontlines are the most vulnerable. The surge in COVID-19 cases have led the hospitals to implement revised protocols to tackle the extraordinarily high call volumes, critical care capacity issues, supply shortages, and limited testing facilities. Hospitals already running to full capacity and over utilized ICUs have been left to redesign patient flow and implementing strategies like shortening lengths of stay for patients, opting for home healthcare for non-critical patients and rather reserve hospital capacity for the critically ill. Preparedness of private healthcare settings have shown tremendous variation across states by emphasizing upon indigenous capacity to develop Rapid Diagnostic Testing kits, PPE for health personnel, and ensuring availability of medical equipment. This session aims to focus on how the Private healthcare at the forefront is combating the pandemic in terms of strategy, preparedness, resource mobilization and first point of contact.
Pharmacelliticals	Convenor of Scientific Program- <b>Dr Arati Verma</b> , Sr Vice President - Medical Quality, Max Healthcare
Chemicals and Fertilizers, GoI*	<u>Chair &amp; Moderator:</u> <b>Dr Nandakumar Jairam,</b> Advisor, FICCI Health Insurance Committee; Chairman & CEO, Columbia Asia Hospitals
Practice, BCG India	<ul> <li>Panelists-</li> <li>Dr Alok Roy, Chair-FICCI Health Services Committee and Chairman, Medica Group of Hospitals</li> </ul>
Panelists-  Mr Glenn Saldanha, CMD, Glenmark*	<ul> <li>Dr Anupam Sibal, Group Medical Director, Apollo Hospitals Group</li> </ul>



<ul> <li>Mr Gagan Singh Bedi, MD, AstraZeneca Pharma India*</li> <li>Mr Sanjay Murdeshwar, MD, Novartis India</li> <li>Ms Namita Thapar, ED, Emcure</li> <li>Mr Prashant Tandon, Founder &amp; CEO, 1MG*</li> </ul>	<ul> <li>Dr Harish Pillai, Chair, FICCI Medical Value Travel Committee and CEO, Aster India, Aster DM Healthcare</li> <li>Air Marshal Dr B Keshav Rao (Retd), Group Head Medical Operations, Fortis Healthcare</li> <li>Dr Sandeep Buddhiraja, Group Medical Director, Max Healthcare</li> <li>Dr Vinay Agarwal, Past National President- IMA &amp; MD, Pushpanjali Medical Centre</li> </ul>
BREAK 3:45 pm – 4:15 pm	BREAK 4:00 pm – 4:15 pm
3:00 pm – 4:30 pm (Hall-1)	3:00 pm – 4:30 pm (Hall-2)

#### **Diagnostics- Pandemic & Beyond**

The COVID-19 pandemic has resulted in Indian Diagnostic Labs, both Government and Private, reaching great heights with over 1400 labs being pressed into service to diagnose the infection. This has completely altered the existing 'routine' testing and newer workflows have come into being that are demanding both in expertise and conforming to regulatory notifications. This has resulted in delayed diagnostic and follow up tests for patients with life threatening diseases like cancer, advanced end stage renal, liver and other diseases. The core challenges experienced were:

- Delivery of quality reports and maintaining the stipulated turn-aroundtime (TAT)
- Adjusting to frequently changing guidelines from different authorities in different states

Diagnostic industry rose to the occasion in-spite of facing numerous hurdles and continued to deliver quality reports with its head held high. The session will discuss the learnings from these experiences and suggest future changes in 'rules of engagement' between the private and public sector

Convenor- **Dr Ravi Gaur**, Director & Chairman- Medical Strategy & Advisory Board, Oncquest Laboratories Ltd

<u>Chair & Moderator</u>- **(Hony) Brig Dr Arvind Lal**, Advisor, FICCI Health Services Committee and Executive Chairman, Dr Lal PathLabs

## **COVID-19: Spectrum of clinical syndromes, complications**

These unprecedented times have brought the world's scientists and global health professionals together to accelerate the research and development process, and develop new norms and standards to contain the spread of the coronavirus pandemic and help care for those affected. Various studies have found wide ranging estimates of the prevalence of asymptomatic carriers. Comorbidities such as cardiovascular and neurological conditions have led to increase in mortality rates in COVID-19 patients. Although COVID-19 preferentially acts on the respiratory system, several patients have also developed cardiovascular and neurological complications. Paediatric cases with symptoms including fever, cough, diarrhoea, pharyngeal erythema and multisystem inflammatory syndrome have also been reported.

The pandemic has multiple medical, psychological, and socio-economic consequences. Therefore, understanding its pathophysiology and clinical implications for development of novel preventive and therapeutic strategies become imperative. The panellists of this session will discuss the wide spectrum of clinical symptoms, complications, syndromes and co-morbid conditions of COVID-19.

<u>Chair & Moderator:</u> **Dr B K Rao,** Chairman, NABH; Chairman, Department of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital



<u>Presentation</u>- **Mr Rahul Guha,** Managing Director & Partner, Lead - Healthcare and Lifesciences practice, BCG India

#### Panelists -

- Ms Ameera Shah, Managing Director, Metropolis Healthcare
- Dr Ravi Gaur, Director & Chairman- Medical Strategy & Advisory Board,
   Oncquest Laboratories Ltd
- Dr Sujeet Kumar Singh, Director, National Centre for Disease Control (NCDC)
- Mr Narendra Varde, General Manager & Country Head, Abbott Diagnostics
- Dr Sujay Prasad, Medical Director, Neuberg Diagnostics

#### Speakers-

- Dr Tanu Singhal, Pediatrician and Infectious disease specialist, Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai
- Dr V Ramasubramanian, Infectious Disease Specialist, Apollo, Chennai
- Dr Anjan Trikha, Professor, Dept. of Anesthesia and Critical Care, AIIMS
- Dr Neeraj Jain, Chairman and Senior Consultant, Dept of Chest Medicine,
   Sir Ganga Ram Hospital, New Delhi
- Dr Samir Parikh, Director, Mental Health & Behavioural Sciences, Fortis Healthcare

4:45 pm – 5:30 am	Inaugural Session
(Hall-1)	Welcome Address
(/	Dr Sangita Reddy, President, FICCI and Joint MD, Apollo Hospitals Enterprise Ltd
	Theme Address
	Dr Alok Roy, Chair, FICCI Health Services Committee and Chairman, Medica Group of Hospitals
	Keynote Address
	Dr Tedros A Ghebreyesus, Director General, World Health Organisation*
	Release of FICCI-BCG Knowledge Paper on Post-COVID Healthcare
	Inaugural Address
	Shri M Venkaiah Naidu, Hon'ble Vice President of India
	Vote of Thanks
	Dr Harsh Mahajan, Co-Chair, FICCI Health Services Committee & Founder & Chief Radiologist, Mahajan Imaging Centre
	On Dais
	Mr Dilip Chenoy, Secretary General, FICCI
	Session Moderator
	Ms Shobha Mishra Ghosh, Assistant Secretary General, FICCI



## Day-2

10:00 am - 11:15 am (Hall-1)

10:00 am - 11:30 am (Hall-2)

## **Structural and Design Changes in Healthcare Facilities**

The healthcare sector has witnessed an unprecedented challenge due to COVID-19 pandemic with healthcare delivery system infrastructure not ready to accommodate and treat the large number of COVID patients requiring special conditions of isolation, air quality management and critical care facilities. Infection control practices, waste management and protection of healthcare fraternity and frontline workers emerged as another big challenge.

While the road to recovery seems elusive immediately post pandemic, ensuring smooth functioning of hospitals will require, new treatment strategies, crisis management plans, structural changes like delineated zones and unidirectional hospital flow aimed towards optimal safety and care.

While a number of innovative changes have been brought as retrofit and quick fix in the existing hospitals, new design strategies being worked out in proposed hospital designs to be pandemic ready for the future.

The session will involve discussions on the impact caused by the pandemic on the healthcare facilities and their infrastructure and how reconfiguring our hospitals facilities in terms of design and structure into 'Future Hospitals' will help us operate within this new reality or similar situations in times to come so that any future pandemics, the healthcare infrastructure remains pandemic-ready.

<u>Convenor & Moderator</u>- **Dr Y P Bhatia**, Managing Director, Astron Hospital & Healthcare Consultants Pvt Ltd

<u>Chair</u>- **Dr Shakti Gupta**, Professor & Medical Superintendent, AIIMS Panelists-

- Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare
- Mr Ashish Rakheja, Managing Partner, AEON Integrated Building Design
- Dr Sanjeev K Singh, Medical Superintendent at Amrita Institute of Medical Sciences

## **Nuances of Diagnostics for COVID-19**

India has significantly ramped up COVID-19 testing from a "one lab, one test" scenario in January to 8 lakh tests a day through more than 1400 labs in August mid. Although a network of 106 labs for viral research was prepared following the SARS of 2009, the only lab that was capable of doing the specialised molecular viral diagnosis at the time of outbreak was in Pune. The testing capacity was accelerated within a span of 4-6 weeks, driven by strategic public-private collaboration and extensive training of human resources across labs and medical colleges.

However, matching supply with demand has been a bottleneck, as full capacity of laboratory-testing remains unutilized. Although RT-PCR remains the gold standard technique for COVID-19 diagnosis, other rapid testing methods such as antigen and antibody-based immunoassays as well as imaging techniques like chest X-ray and CT scans have aided in diagnosis.

This session will entail discussions by experts on the transformation of diagnostic testing in India, emergence and use of new tests as well as their efficacy for prognosis, diagnosis and treatment.

<u>Chair & Moderator:</u> **Dr Harsh Mahajan,** Co-Chair, FICCI Health Services Committee & Founder & Chief Radiologist, Mahajan Imaging

#### Panelists-

- Dr G S K Velu Chairman & Managing Director, Trivitron Healthcare
- Dr Om Manchanda, MD, Dr Lal PathLabs
- Dr Navin Dang, Microbiologist & Director, Dr Dang's Lab Pvt. Ltd
- Dr Nivedita Gupta, Scientist, Epidemiology and Communicable Diseases, ICMR

www.ficci-heal.com

6



<ul> <li>Col Saroj Patnaik, Associate Professor, Department of Hospital Administration AFMC</li> </ul>	<ul> <li>Dr Anurag Agarwal, Director, CSIR-Institute of Genomics and Integrative Biology</li> </ul>
BREAK 11:15 am – 12:30 pm	BREAK 11:30 am – 12:30 pm
12:30 pm – 1:45 pm (Hall-1)	12:30 pm – 2:00 pm (Hall-2)
HR Practices- Changing Models	Therapies for COVID-19: Current therapies and their effectiveness?
COVID-19 has brought significant disruptions in the way businesses work, and is accelerating one of the greatest workplace transformations of our lifetime. Organisations have been constantly reinventing practically every process and policy, especially those related to Human Resources. One of the key aspects is, the way organizations are restructuring and realigning their employee engagement and retention models, while trying to ensure outcomes.  Keeping in mind that the pandemic is still looming large, the management, HR and administrative units of all healthcare organisations will need to work collectively to streamline their recruitment strategy, ensure Adequate Learning and development to upskill their employees, proactively engage with employees at all levels and adapt operations to the new post-COVID work environment and ensure long term sustainability. This session will throw light upon Transformation in HR Practices during COVID with emphasis on new and changing models of engagement and service.	As the number of positive cases keep on multiplying, our healthcare system is becoming increasingly strained leaving the country in desperate need of a safe and effective treatment for COVID-19. Since the start of the outbreak, doctors, scientists, pharmaceutical companies, governments across the world are scrambling to find a cure. Several medicines are undergoing investigation through clinical trials as potential treatments for COVID-19. These vary from antiviral drugs claiming to prevent virus from multiplying to immune modulators for strengthening the immune system. Two of the most high-profile drug candidates being clinically tested are Remdesivir and Hydroxychloroquine which are under debate emphasizing on large, robust, randomised, placebo-controlled clinical trials. In these unprecedented times, innovators are sprinting towards treatment and therapies that can address the pandemic.  The session aims to discuss the effectiveness of current therapies and chart out clinical pathways for greater standardization of treatment regimens and sequencing as well as improved outcomes, from both a quality of life and a clinical-outcomes for COVID-19.
<u>Convenor &amp; Moderator</u> - <b>Mr Gautam Khanna</b> , Co-Chair, FICCI Healthservices Committee and CEO, P D Hinduja Hospital <u>Speakers</u> -	<u>Chair &amp; Moderator:</u> <b>Dr G C Khilnani,</b> Chairman, PSRI Institute of Pulmonary, Critical care and Sleep Medicine. Formerly Professor and Head, Dept of Pulmonary, Critical care and Sleep Medicine AIIMS, New Delhi
<ul> <li>Dr Sudarshan Ballal, Chairman, Manipal Hospitals</li> <li>Mr S V Kiran, Sr Vice President &amp; Head- HR, Apollo Hospitals</li> <li>Ms Angela Ryan, Group Chief Human Resources Officer, IHH Healthcare</li> </ul>	<ul> <li>Presentations-</li> <li>Drug Therapy for Mild disease- Dr D J Christopher, Prof and Head, Dept of Pulmonary Medicine, CMC, Vellore</li> </ul>



- Mr Paul William Martin, Corporate HR Strategy Business Partner, Abu Dhabi Health Services Company- SEHA
- Dr Neil Sequeira, VP- Human Resources and Administration, Kokilaben Dhirubhai Ambani Hospital
- Drug Therapy for moderate and severe disease- Dr Raja Dhar, Director,
   Department of Pulmonology, Fortis Hospital Kolkata
- Dr Ankur Puri, Pulmonary & Critical Care Specialist, University of Pittsburgh Medical Centre (UPMC)

#### Panelists-

- Dr T S Kler, Chairman, PSRI Institute of Cardiac Sciences, New Delhi
- Dr S K Chhabra, HOD, Pulmonary, Sleep and Critical Care Medicine,
   Primus superspeciality hospital, New Delhi
- Dr Anjan Trikha, Professor, Dept of Anaesthesia, Critical Care and Sleep Medicine, AIIMS, New Delhi
- Dr D J Christopher, Prof and Head, Dept of Pulmonary Medicine, CMC, Vellore
- Dr Raja Dhar, Director, Department of Pulmonology, Fortis Hospital Kolkata

#### 10:00 am - 1:00 pm (Hall-3)

### **MedTech Bootcamp**

An innovation ecosystem in the country needs pool of talent that can think out of box and work in multidisciplinary subjects to innovate; access to funds; facilitating regulatory environment; Intellectual Property laws;. To take them to next level, a robust medtech ecosystem robustness a network of OEMs, industrial designer, Medical Parks etc. for developing strategic partnerships. In India we need to strengthen this segment to make India Atma nirbhar in manufacturing of indigenous Medtech innovative products.

According to The State of Startup Ecosystem Report 2018, there are a total of 4,892 startups in the Indian healthtech space, which have raised a total of \$504 Mn between 2014-2018. In 2019, the healthtech sector recorded total funding of \$586.93 Mn, an increase of over 10% in the amount of funding from the previous year. In 2020, as world continues to grapple with the covid-19 pandemic, there has seen a mammoth growth in the healthcare innovation space. In addition to this, the launch of National Digital Health Mission (NDHM) and the government efforts to digitise the Indian healthcare segment will boost the confidence of the entrepreneurs working in this sector.

Even today, entering the healthcare industry isn't the same as starting an IT or technology company. Indian innovators face huge challenges in commercializing their products and making their product fit for the global markets. Some of the key issues are complex regulatory environment, limited availability of funds, inadequate ecosystem support for example, POC & manufacturing, absence of indigenous 'quality certification' authority, limited availability of skilled workforce



and lack of focus on health technology assessment. The need of the hour is to provide a supportive Health-tech ecosystem for Indian innovators to provide them access to necessary knowledge, investors, and manufacturing partners to collaborate.

## Panel Discussion- 'Bridging the Gap: Innovation to Commercialization through Partnerships'

Moderator- Mr Sashi Kumar, Co-Chair, FICCI Medical Devices Committee; Managing Director, Phoenix Medical Systems

#### Panelists:

- Dr Manish Diwan, Head Strategic Partnership & Entrepreneurship Development, BIRAC
- Dr G.S.K. Velu Chairman & Managing Director, Trivitron Healthcare
- Mr Ravindranath R, Sr. DGM, Medical Electronics Division, Bharat Electronics (BEL)
- Prof. Praveen Nahar, Director, National Institute of Design, Ahmedabad
- Mr Nitin Sisodia, Founder and CEO, Sohum Innovation Lab
- Ms Tulika Puri Katyal, Founder, Center for Design & Innovation and Vice Chairperson I IVS-School of Design
- Mr Vinod G Pillai, VP, Sourcing, HLL Lifecare\*
- Dr Jitendra Sharma, MD & CEO, Andhra Med Tech Zone\*

## **Pitch / Presentations by Innovators**

Moderator – Mr Shyam Vasudev Rao, Co-Chair, FICCI Medical Devices Committee; Founder & Director, Forus Health & Renalyx health systems

BREAK 1:45 pm – 2:30 pm	BREAK 2:00 pm – 2:30 pm
2:30 pm – 3:45 pm (Hall-1)	2:30 pm – 4:00 pm (Hall-2)
Realizing Atmanirbhar Bharat through Make in India	Non-COVID treatment: Changing protocols
Atmanirbhar Bharat Abhiyan lays down an intent to re-energise, revamp and reinforce a strong industrial and manufacturing sector for India's long-term growth and self-reliance in the post-COVID world. It is expected to kickstart Make in India 2.0, with an immense opportunity for the medical devices sector too. Although the Indian medical device industry is amongst the top 20 markets for	As the emaciated Indian healthcare system attempts to break the tide of the novel coronavirus pandemic, perhaps the highest cost for this fight is being borne by the non-COVID-19 patients. Reduced access to both out-patient and hospitalisation services has been proving detrimental for several patients, especially non-communicable diseases (NCDs), as well as those that needed
medical devices in the world and 4th in Asia, we are still highly import dependent	emergency care.



for high end products. The COVID crisis has proved to be an opportunity for collaborations for augmenting the manufacturing capacity in the country, and the momentum is expected to continue.

This session will focus on the learnings from the global best practices and how countries like Ireland, Malaysia, Germany etc. have been successful in becoming self-reliant in the medical devices sector. Further the session will deliberate on the future projections for the sector and the opportunities seen in light of *Atmanirbhar Bharat*.

It has been imperative for health systems to address these conditions differently. Apart from life sustaining treatment, there was need for continuity of care for many conditions like cancer, thalassemia, kidney failures, transplants, cardiac issues etc.

This session will deliberate upon the changing protocols for treatment of Non-COVID patients, measures for segregation of COVID and non-COVID areas as well as changing infection control procedures in the wake of the pandemic.

<u>Convenor & Moderator</u>- **Mr Badhri Iyengar**, Chair, FICCI Medical Devices Committee; Cluster Managing Director - South Asia (SAARC) & South East Asia (ASEAN), Smith & Nephew

<u>Keynote Address & Session Chair</u>- **Dr Guruprasad Mohapatra,** Secretary, Department for Promotion of Industry and Internal Trade, GoI\*

#### Panelists -

- Ms Tanaz Buhariwalla, Director- India, IDA Ireland
- Mr Roland Göhde, Chairman of the Board, GHA (German Health Alliance
   – an initiative of BDI) & Senior Managing Director at Sysmex Partec GmbH\*
- Mr Ahmad Khairuddin, Deputy CEO, Malaysian Investment Development Authority\*
- Dr Jitender Sharma, Managing Director, AMTZ
- Mr Madan R Krishnan, VP-MD India Subcontinent (South Asia) Medtronic

BREAK 3:45 pm - 4:15 pm

<u>Chair & Moderator:</u> **Dr N Subramanian,** Co-Chair, FICCI Health Services Committee and Director, Medical Services & Sr. Consultant- Urology, Indraprastha Apollo Hospitals

#### Panelists-

- Dr Mario Musella, Professor of Surgery, University of Naples, Italy,
   Department of Advanced Biomedical Sciences; Former President,
   International MGB OAGB Club for Bariatric Surgery
- Mr Pala Rajesh, Sr. Vice President, Royal College of Surgeons of Edinburgh
- Professor Kazunori Kasama, Director, Weight Loss and Metabolic Surgery center, Yotsuya Medical Cube, Japan; President, IFSO APC (International Federation of Surgery for Obesity and metabolic disorders Asia Pacific Chapter)
- Dr Ramen Goel, Bariatric and Weight Loss surgeon, Hinduja Health Care, Mumbai; President of IAGES; (Society of Indian Laparoscopic Surgeons)

BREAK 4:00 pm - 4:15 pm

4:15 pm – 5:30 pm (Hall-1)

4:15 pm – 4:45 pm (Hall-1)

## Science of Ayurveda

India's traditional system of medicine and specifically Ayurveda has the potential to complement the modern medicine and also offer a novel and effective way to manage the respiratory disorders and infectious diseases, including COVID-19. Although Ayurveda is based on scientific knowledge and the tradition has gained popularity in the Western world, it is still considered an alternative medical treatment in India.

## **Cyber Security in Healthcare**

Digital infrastructure today faces a persistent threat of cybersecurity attacks leading to data theft, corruption and hurdles for business operations. Healthcare sector is no exception to this threat, in fact there has been an increase of over 150% in cyber-attacks during the COVID-19 global pandemic. The Indian healthcare sector is particularly vulnerable due to low levels of awareness and inadequate Cybersecurity measures. The impending policy



While the need for scientific evaluation of Ayurveda has been recognized for a long time, Ayurveda's holistic concepts have demonstrated personalized approach involving constitutional assessment, which can guide primary prevention, diagnosis and therapeutics.

The Panellists of this session will share key developments, global recognition and potential of Ayurveda, and its integration with modern medicine, for tackling highly infectious disease like COVID.

reforms in the healthcare sector will have a major impact on patient data security and make companies liable for data breaches.

#### This session will have:

- Experts Present an Overview of Cybersecurity in Healthcare Sector
- Announce the FICCI-Cyberwis "Healthcare Cybersecurity' Knowledge Paper

# <u>Convenor & Moderator</u>- **Mr Arvind Varchaswi**, Co-Chair, FICCI AYUSH Committee and Managing Director, Sri Sri Tattva

#### Panelists -

- Dr Geetha Krishnan, India Representative- AYUSH, WHO
- Prof Tanuja Manoj Nesari, Director, All India Institute of Ayurveda (AIIA), Ministry of AYUSH, Gol
- Vd (Dr) K S Dhiman, Director General, Central Council for Research in Ayurvedic Sciences (CCRAS)
- Mr Anurag Sharma, Chair FICCI AYUSH Committee, JMD, Baidyanath\*
- Mr Pradeep Multani, Co-Chair FICCI AYUSH Committee, Chairman, Multani Pharmaceuticals
- **Dr Arati Verma**, Sr Vice President Medical Quality, Max Healthcare

#### Speakers -

- Mr Munjal Shroff, Founder, Cyberwis Pte. Ltd.
- Mr Sunil Bangalore, President & CEO, CyQureX Systems
- Mr Samir Aksekar, Director CyberWis Pte. Ltd.

5:30 pm - 6:00 pm (Hall-1)

## Keynote Address-

'Macro-Economic Impact of COVID on World & India'

Prof Arvind Panagariya, Professor of Economics and the Jagdish Bhagwati Professor of Indian Political Economy, Columbia University\*

In conversation with Dr Alok Roy, Chair, FICCI Health Services Committee and Chairman, Medica Group of Hospitals

Introduction by Ms Shobha Mishra Ghosh, Assistant Secretary General, FICCI



## Day-3

10:00 am - 12:00 noon (Hall-1)

## **Digital Revolution - Going Viral!**

As our healthcare systems brace for appropriately responding to the pandemic, need for transformation of healthcare delivery by unleashing the power of digital technologies has been felt more than ever. The massive surge in demand for digital health solutions during the pandemic is expected to continue to grow even in a post-COVID world.

While telemedicine and virtual consultations have already proven as apposite solutions, other digital health technologies have shown their potential to be integrated into the mainstream healthcare delivery. This is encouraging countries to implement long-term digital health tools, enhance the interoperability of electronic health records as well as explore greater use of exponential technologies like Robotics, AI and Data analytics in routine diagnostics and care delivery. The panelists of the session will highlight the emergence of digital health technologies as successful solutions to tackle the pandemic and how a robust, scalable and integrated digital healthcare infrastructure will shape the future of care delivery.

# <u>Convenor & Moderator</u>- **Dr Vidur Mahajan**, Head- R&D, CARING and Associate Director, Mahajan Imaging Speakers -

- Dr Scott Atlas, Advisor, White House Coronavirus Task Force and Robert Wesson Senior Fellow in Scientific Philosophy and Public Policy at Stanford University, USA
- Dr Indu Bhushan, CEO, AB-PMJAY and the National Health Authority (NHA), Gol
- Mr Kieran Murphy, Global CEO, GE Healthcare
- Dr Jan Herzhoff, President- Global Health Markets, Elsevier
- Dr Sangita Reddy, President-FICCI & Joint MD, Apollo Hospitals
- Mr Bart Janssens, MD and Senior Partner, The Boston Consulting Group Inc

BREAK 12:00 noon – 12:30 pm		
12:30 pm – 2:00 pm (Hall-1)	12:30 pm – 2:00 pm (Hall-2)	
Best Practices for Management of COVID	2020 (Year of the Nurse)- Before and Beyond	



Crisis breed opportunities. Deeper the crisis, the better the opportunity can be. While the pandemic continues to drain our already vulnerable health systems, it has simultaneously opened a floodgate of innovations, ideas, and dialogues for testing, treatment as well as community engagement for combating the pandemic.

Many States have adopted as well as demonstrated new strategies and approaches for containment of the virus and risk communication with the community. Organizations have come up with patient-centric innovations, technologies and solutions which can be widely adopted. We have also witnessed various stakeholder collaborations- whether it was for augmenting the supply for safety kits or ventilators or for ramping up diagnostics. Many adaptations have been made for scaling up services in low-resource settings and across geographies, aimed towards making healthcare affordable and accessible.

This session will highlight best practices and examples from various stakeholders that have been successful in managing COVID and that would lead the planning and preparation for future pandemics.

<u>Convenor & Moderator</u>- **Dr Suneela Garg,** National President Elect- IAPSM, Director Professor HAG, Ex Head (CM) Sub Dean, MAMC & Head Community Medicine, FMS

#### Panelists -

- Ms K K Shailaja, Minister for Health, Social Justice and Woman and Child Development, State of Kerala\*
- Dr Roderico H. Ofrin, WHO Representative to India\*
- Dr Mahesh Verma, Head- COVID-19 Advisory Body to Delhi Government and Vice-Chancellor of Guru Gobind Singh Indraprastha University
- Dr Randeep Guleria, Director, AIIMS-Delhi
- Mr Kiran Dighavkar, Assistant Municipal Commissioner- G North, BMC, Maharashtra; Lead on Dharavi Model
- Dr Sagar Galwankar, CEO, INDUSEM and Associate Professor, Florida State University College of Medicine

Nurses are the frontline healthcare professionals who have played a vital role during the pandemic for providing safe and protective environment for the vulnerable and the affected while working long hours, isolated from children and family. From educating the patient and providing support to individuals in high-risk categories to screening suspected cases, implementing proper hygiene practices, medication storage and handing, they have played multiple roles successfully. It could not be more-timely that the World Health Organization designated 2020 as the International Year of the Nurse and the Midwife. Studies have shown the psychological impacts and long-term consequences they undergo due to long working hours in stressful conditions as they provide direct care to the affected despite the uncertainty. Ensuring they are well supported and facilitated to provide high quality healthcare during such unprecedented times is the need of the hour.

This session will involve discussion on Life of a Nurse working during the COVID-19, challenges faced, and getting nurses on board for COVID care.

<u>Chair & Moderator</u>- **Dr N Subramanian,** Co-Chair, FICCI Health Services Committee and Director, Medical Services & Sr. Consultant- Urology, Indraprastha Apollo Hospitals

#### Panelists-

- Capt Sandhya S Pandey, Corporate Chief of Nursing Pan Fortis, Fortis Healthcare
- Capt Usha Banerjee, Group Director, Nursing, Apollo
- Ms Ajitha PS, COO, Avitis Institute of Medical Sciences
- Ms Thankam Gomez, Founder & CEO, Cygnia Healthcare; President, Association of Nurse Executives (India)



Dr Tim Hawkins, MD, Commercial Clinical Solutions- EMEALAAP, Elsevier	
BREAK 2:00 pm – 2:30 pm	BREAK 2:00 pm – 2:30 pm
2:30 pm – 3:45 pm (Hall-1)	2:30 pm – 4:00 pm (Hall-2)
Home Healthcare- the changing paradigm	Vaccines for COVID 19: Have we reached the finishing line?
As the government envisions aspirational reforms in healthcare sector and moves closer to implementing new ways to tackle the pandemic, home healthcare has a critical role to play in 'out-of-hospital' care delivery. Telehealth consultations seem to be the game changer for the healthcare system expanding the home healthcare sector faster-than-anticipated. Home healthcare has helped reduce the hospital patient load by catering to patients with mild symptoms at home, emphasizing on regular monitoring of temperature, vitals and oxygen levels. It has also helped in keeping the vulnerable elderly population safe at home, cutting down on their risk of infection.  As we envision a transformed future for integrated healthcare delivery in India, out of hospital and home healthcare will form a key component of the new delivery models.  The session will entail deliberations on future models, technologies and tools for enhancing home healthcare in the post pandemic scenario.	It is well established that vaccines are the most effective method to alleviate the mortality and morbidity associated with response to a pandemic. Globally, various biopharma companies have accelerated their R&D processes since the outbreak and many of them are making collaborative efforts to develop and manufacture effective vaccines to address the pandemic. As the pandemic continues to unfold, the pursuit of a vaccine intensifies. With multiple vaccines under development and scientists working round the clock we are one step closer to putting our masks away. According to the Ministry of Science and Technology, in recent years, India has emerged as one of the significant vaccine manufacturing hubs with Indian manufacturers accounting for 60 per cent of vaccine supplies made to UNICEF. Vaccines including Covaxin (Bharat Biotech), and ZyCov-D (Zydus Cadila) have entered the human trials stage. By far, vaccines have been considered to be the most effective weapon to protect people from pandemic irrespective of the lengthy multi-step development phases. The session will focus on history and the need for vaccines, their role in managing a pandemic, insights on stages of clinical trials for COVID-19 and its ultimate plan of execution.
<u>Convenor &amp; Moderator</u> - <b>Dr Gaurav Thukral</b> , EVP & COO, HealthCare atHOME <u>Panelists</u> —	<u>Chair</u> - <b>Dr YK Gupta</b> , Professor and Head, Department of Pharmacology, AIIMS* <u>Convenor &amp; Moderator</u> : <b>Dr Ajay Sharma</b> , Head- Government Affairs,  AstraZeneca Pharma India
Ms Arti Ahuja, Additional Secretary, MoHFW, GoI*	Panelists-
<ul> <li>Dr Atul Mohan Kochhar, CEO, NABH</li> </ul>	Dr Arun Wadhwa, Consultant Paediatrician; Visiting Consultant Rainbow
<ul> <li>Mr Mayank Bathwal, CEO, Aditya Birla Health Insurance</li> </ul>	Children's Hospital
<ul> <li>Mr Pavan Mocherla, Managing Director, BD India</li> </ul>	Dr Aviral Roy, Consultant, Critical Care, Medica Super Specialty Hospital



<ul> <li>Mr Vishal Dembla, Chief Business Officer, ConnectedLife Health</li> </ul>	<ul> <li>Dr Madhur Gupta, Technical Officer-Pharmaceuticals, WHO Country Office for India</li> <li>Dr Murtaza Khorakiwala, Managing Director, Wockhardt</li> <li>Mr Sharad Goswami, Senior Director- Public Affairs, Pfizer India</li> </ul>
BREAK 3:45 pm – 4:15 pm	BREAK 4:00 pm – 4:15 pm

4:15 pm - 5:30 pm (Hall-1)

### **Learnings for the Future**

The pandemic has created unprecedented disruption for the global health community and overstretched healthcare infrastructure of even the most developed countries. It has forced healthcare institutions and regulatory bodies to re-think, restructure and reform the existing processes and system and seek more advanced and alternative ways of providing healthcare.

In India, while healthcare has not been very high on the political or public agenda, COVID-19 has triggered the much-needed government focus towards healthcare infrastructure development. It is evident that the pandemic will bring in a huge paradigm shift in not only the way medicine will be practiced in future, but the way healthcare is envisioned- by the government, the industry as well as the community at large.

The session will focus on the learnings that COVID-19 has brought in for the future of healthcare- in terms of government focus, enhanced preventive and promotive care as well as improved stakeholder collaborations.

Convenor- Dr Harsh Mahajan, Co-Chair, FICCI Health Services Committee & Founder & Chief Radiologist, Mahajan Imaging

<u>Chair</u>- **Dr Himanta Biswa Sarma**, Hon'ble Finance Minister, Government of Assam and Convener, North-East Democratic Alliance (NEDA)\* Moderator- **Mr Rahul Kanwal**, News Director, India Today\*

#### Panelists -

- Dr V K Paul, Member (Health), NITI Aayog, Gol
- Mr Rajesh Bhushan, Secretary, MoHFW, Gol
- Mr Vijay K Dev, Chief Secretary, Govt of NCT of Delhi\*
- Mr Sukumar Ranganathan, Editor, Hindustan Times
- Dr Preetha Reddy, Vice Chairperson, Apollo Hospitals

## 5:30 pm - 6:00 pm (Hall-1)



## **Valedictory Session**

## 'How the World will prepare for Post-COVID'

Keynote Address

**Prof Richard C Horton** FRCP FMedSci, Editor-in-Chief, The Lancet

**Dr Sangita Reddy**, President-FICCI & Joint MD, Apollo Hospitals

Dr Alok Roy, Chair, FICCI Health Services Committee and Chairman, Medica Group of Hospitals

**Dr Narottam Puri**, Advisor, FICCI Health Services Committee; Former Chairman- NABH; Advisor-Medical Operations & Chairman- Fortis Medical Council, Fortis Healthcare Ltd.

Vote of Thanks by Mr Dilip Chenoy, Secretary General, FICCI

Session Moderated by Ms Shobha Mishra Ghosh, Assistant Secretary General, FICCI

\*Invited